-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $17

Benzinga·11/06/2025 23:06:22
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $20 to $17.